

HAIMBIO

Haim[®] *Bio*
for Better Life[™]

Haimbio's Starvanip is a metabolism-based cancer therapy that kills cancer cells by starving them of energy.

FIGHTING CANCER BETTER

Though existing anti-cancer drugs have helped countless people, they also suffer from serious limitations.

- The first generation of anticancer therapy, chemical anticancer drugs, affect both cancer cells and normal cells and induces resistance to other anticancer drugs.
- The second generation, targeted anticancer therapy, works only in patients with mutations in certain genes. Repeated administration causes resistance and if recurrence occurs, it's likely to be metastatic.
- The third generation, anticancer immunotherapy, has a low patient response rate and has serious side effects, including potentially causing cytokine storms.

STARVANIP: A METABOLISM-BASED SOLUTION

Starvanip inhibits cancer cell growth and induces apoptosis -- the death of cancer cells. It does this by inhibiting the energy source of cancer cells, dramatically reducing side effects such as harm to normal cells and reducing the toxicity of current anticancer therapies. The drug will also improve the rate of response and target a wider range of cancers.

EFFECTIVE AGAINST 12 TYPES OF CANCER

Preclinical trials have demonstrated efficacy with 12 types of cancer.

Also, pre-clinical trials of Starvanip have demonstrated significant reductions of tumor sizes and increases of cancer cell death with almost no death of normal cells.

8 PATENTS IN KOREA AND ABROAD

Starvanip has eight patents in South Korea, some of which are also registered in the US, Europe, China, Japan, Hong Kong, Israel and India.

A RESEARCH-CENTRIC TEAM

Founder and CEO Hong-Yeoul Kim is a professor at Kyunghee University's College of Korean Medicine and an expert on public health for South Korea's Ministry of Health.

The company's Scientific Advisory Board includes experts from some of South Korea's finest medical establishments, including Yonsei Medical Center and the National Cancer Center, as well as from international partners Axcelead Drug Discovery Partners and Sekisui Medical. The board also includes:

Dr. Soo Youl Kim, and Professor Jae Ho Jung, nonexecutive director. They invented the technology, which was transferred from the National Cancer Center and Yonsei Medical Center.

HITTING THE GROUND RUNNING IN THE USA

Haimbio will begin full-scale B2G, B2B and B2C sales after securing ODD (Orphan Disease Designation) from the U.S. FDA in 2023. The company is in phase 1 clinical trials at South Korea's Severance Hospital and will begin direct sales after completing phase 2 clinical trials in the United States in five years.

A USD 90 BILLION GLOBAL MARKET. AND GROWING.

The global market of cancer drugs is \$90B USD in 2020, with an expected annual growth rate of 8%. Haimbio will secure 5% of this market, particularly targeting the countries where it has the patent right of 12 types of cancer.

CONTACTS

+82-10-8480-5890
www.haimbio.com

Hyunmin Kim | hmkim@haimbio.com